ClearStar sees 'significant' uptick in revenues

Medical screening technology group ClearStar has seen a "significant" uptick in revenues since 31 May after having been hit hard by the Covid-19 pandemic.

ClearStar said on Tuesday that the Covid-19 outbreak had significantly impacted the business due to the impact on labour markets.

However, the AIM-listed company highlighted that its performance had steadied following the reopening of all 50 US states.

"While we have not yet returned to our pre-Covid-19 revenue run rate, the increase in sales so far is extremely encouraging," said chairman Barney Quinn.

"As the US economic recovery progresses and our customers are able to resume more normal trading, we expect this growth in our activity to continue."

ClearStar also said it had continued to maintain tight control over costs amid growing sales activity and highlighted that it was also benefiting from mitigation measures implemented in response to the Covid-19 crisis.

As of 1115 BST, ClearStar shares were up 5.26% at 40.0p.